December 1st 2024.
For the first time in 30 years, those suffering from endometriosis will have access to a new, affordable treatment. The drug Visanne, also known as dienogest, will now be available under the Pharmaceutical Benefits Scheme. Health Minister Mark Butler is expected to announce this exciting news today.
Until now, Visanne could cost anywhere from $380 to $800 per year, making it difficult for many to afford. However, with its listing under the Pharmaceutical Benefits Scheme, those with pension and concession cards will only have to pay $90 for a year's supply. This will make a significant difference for those living with endometriosis.
Visanne is a daily tablet that works by inhibiting ovulation and menstruation using the hormone progesterone. This helps to suppress and shrink the growth of abnormal tissue, which is a common characteristic of endometriosis. This tissue can grow outside the womb, causing inflammation, scarring, and painful adhesions that can affect the pelvic organs.
Unfortunately, endometriosis is a debilitating condition that affects about 1 million women in Australia. On average, it takes six years for a woman to receive a diagnosis. Obstetrician and gynecologist Professor Jason Abbott from the University of Sydney has seen a 40% increase in hospital admissions for endometriosis in the past decade.
He believes that the listing of Visanne under the Pharmaceutical Benefits Scheme will be great news for many women living with this invisible disease. While there is no cure for endometriosis, access to affordable treatment options is crucial for managing symptoms and improving a patient's quality of life. Even after surgery, medication is often necessary to help control symptoms that can impact daily activities like work, school, and social life.
Syl Freedman, who was diagnosed with stage four endometriosis at 21, is thrilled about the subsidy. Along with her mother Lesley, she co-founded the non-profit charity EndoActive to raise awareness and provide support for those living with endometriosis. She believes that this news will make a significant difference for endo patients, as the condition can impact every aspect of life, including employment, relationships, and physical and mental health.
In conclusion, the Federal Government's decision to support Australians living with endometriosis by subsidizing Visanne is a commendable and much-needed step. This will provide equal and affordable access to treatment options for those living with this debilitating condition. To stay updated on this and other important news, download the 9News app, available on the Apple App Store and Google Play.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]
